Class Explorer · Cardiovascular
Mineralocorticoid receptor antagonists
Competitive antagonists at the aldosterone receptor in the distal nephron: sodium out, potassium retained, and, in the heart, less fibrosis. The diuretic effect is modest; the outcome benefit is not.
Open the interactive pathwayMembers
SpironolactoneA weak diuretic with a strong survival benefit, and a potassium you must watch.EplerenoneSpironolactone without the gynecomastia, at a price.
Also in this class: Finerenone (non-steroidal, cardiorenal in diabetic kidney disease). Full pages arrive as the library grows.
Compare the members
Spironolactone
- Receptor selectivity
- Non-selective
- Endocrine effects
- Gynecomastia, breast tenderness
- Where it wins
- HFrEF, ascites, resistant hypertension, cheapest
Eplerenone
- Receptor selectivity
- Selective
- Endocrine effects
- Minimal
- Where it wins
- When gynecomastia forces a switch; post-MI HF
Shared across the class
- Indications
- Heart failure with reduced ejection fraction · Resistant hypertension · Ascites in cirrhosis (spironolactone) · Primary aldosteronism
- Adverse effects
- Hyperkalemia · Acute kidney injury when volume-deplete · Gynecomastia (spironolactone)
- Contraindications
- Hyperkalemia at baseline · Severe renal impairment · Addison disease
- Monitoring
- Potassium and creatinine at baseline, one week, one month, then quarterly · Sooner after any dose increase, illness, or added RAAS blocker
What makes each agent different
- Spironolactone is non-selective and binds androgen and progesterone receptors too: gynecomastia, breast tenderness and menstrual irregularity are its own, not the class's.
- Eplerenone is selective and largely free of those endocrine effects, at greater cost and with a shorter half-life.
- Only spironolactone has the ascites evidence; only spironolactone is cheap enough to be the reflex first choice everywhere else.
The dose that helps the heart is far below the dose that produces a diuresis. A patient can be on a full 'heart-failure dose' and pass no extra urine at all.
The most dangerous day for an MRA patient is the day they get diarrhoea and keep taking it.
Last reviewed 2026-08-16 · Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th ed.